Stereotactic MRI-guided radiation therapy for localized prostate cancer (SMILE): a prospective, multicentric phase-II-trial
Jonas Ristau(Heidelberg University), Stefan A. Koerber(German Cancer Research Center), Carolin Buchele(Heidelberg University), Lukas Baumann(Statistics Austria), Claus Belka(LMU Klinikum), Sebastian Klüter(Heidelberg University), Nicolaus Andratschke(University Hospital of Zurich), Cornelia Jäkel(Heidelberg University), Maximilian Niyazi(German Cancer Research Center), Klaus Herfarth(Heidelberg University), Juliane Hörner‐Rieber(Düsseldorf University Hospital), Jürgen Debus(Heidelberg University), Helena Garcia Schüler(University of Zurich), M Li(LMU Klinikum), Matthias Gückenberger(University Hospital of Zurich)
Cited by 18
Related Papers
Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
|The Lancet Oncology|2020|1.1k
Defining oligometastatic disease from a radiation oncology perspective: An ESTRO-ASTRO consensus document
|Radiotherapy and Oncology|2020|646
EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours
|Annals of Oncology|2021|577
A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection
|Journal of the American Society of Nephrology|2017|302